This umbrella review synthesizes evidence from systematic reviews to assess the effectiveness, cost-effectiveness, and implementation barriers and facilitators of ASPs across diverse healthcare settings. The included 55 reviews demonstrated that ASPs consistently reduce antibiotic consumption-achieving reductions up to 91%-and improve adherence to prescribing guidelines. Significant declines in resistance rates for key pathogens, such as MRSA and ESBL-producing organisms, were reported. Although effects on mortality and hospital length of stay were variable, most studies confirmed substantial cost-savings (up to 82% reduction in antibiotic expenditures). Implementation barriers primarily included limited resources, insufficient data infrastructure, and prescriber resistance, while strong organizational support and multidisciplinary collaboration emerged as key facilitators. ASPs are both clinically effective and economically advantageous in diverse healthcare settings. Tailored strategies that address local barriers and leverage existing infrastructure are essential for sustainable implementation.
This single-center, retrospective, cost-minimization analysis compared treatment with oritavancin and dalbavancin vs vancomycin and daptomycin in 55 adult patients (22 received oritavancin, 15 received dalbavancin, 10 received vancomycin, and 8 received daptomycin). The mean cost of therapy per patient receiving oritavancin, dalbavancin, vancomycin, and daptomycin was $35,630, $59,612, 3$73,33, and $73,708, respectively. The cost of using oritavancin and dalbavancin was lower than that of vancomycin and daptomycin, especially for osteomyelitis. As safety and effectiveness data continue to emerge, the use of long-acting lipoglycopeptides appears to be an increasingly attractive alternative to traditional outpatient antimicrobial therapy.
The aim of the present analysis was to estimate the expenditure, in terms of direct and indirect healthcare costs, for patients hospitalized with a confirmed diagnosis of ABSSSI, evaluating the impact of dalbavancin, compared to the other Standard of Care of the same IV antibiotic class, analysed in the REDS study. The analysis was carried out using data collected as part of the study “Retrospective Effectiveness study of dalbavancin and other Standard of care of the same class IV lipo and glycopeptides) in patients with ABSSSI” (REDS study). In the present analysis, the economic impact of managing patients hospitalized for ABSSSI was estimated by evaluating both the direct healthcare costs relating to hospital and pharmaceutical care and the indirect costs relating to the loss of productivity due to the pathology. The analysis of data from the REDS study made it possible to estimate the economic impact of the management of patients hospitalized for ABSSSI, depending on the treatment received during hospitalization. The results highlighted a reduction in costs for patients treated with dalbavancin, both for direct healthcare costs and indirect costs, over the entire observation period. Again, the reduction increases, reaching statistical significance, and the costs are evaluated from the beginning of the treatment.